Insider Buying: Keros Therapeutics, Inc. (NASDAQ:KROS) Major Shareholder Purchases 934,258 Shares of Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the business’s stock in a transaction dated Wednesday, April 9th. The stock was bought at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider now owns 4,392,737 shares of the company’s stock, valued at approximately $44,498,425.81. The trade was a 27.01 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Keros Therapeutics Stock Down 0.5 %

KROS stock opened at $12.18 on Monday. The company has a market cap of $494.05 million, a price-to-earnings ratio of -2.34 and a beta of 1.39. The business has a fifty day simple moving average of $10.91 and a 200-day simple moving average of $30.62. Keros Therapeutics, Inc. has a 52 week low of $9.12 and a 52 week high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.22. The company had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. As a group, analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KROS has been the subject of a number of recent research reports. Guggenheim reiterated a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Scotiabank lowered their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a report on Thursday, January 16th. Cantor Fitzgerald downgraded shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 21st. Truist Financial lowered their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, April 9th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Keros Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. AlphaQuest LLC grew its stake in Keros Therapeutics by 469.0% during the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after buying an additional 2,964 shares during the period. Virtus ETF Advisers LLC lifted its holdings in shares of Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock valued at $61,000 after acquiring an additional 1,998 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Keros Therapeutics during the 4th quarter worth $90,000. Exchange Traded Concepts LLC acquired a new stake in Keros Therapeutics in the 4th quarter valued at $99,000. Finally, CANADA LIFE ASSURANCE Co raised its position in Keros Therapeutics by 207.8% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company’s stock valued at $116,000 after purchasing an additional 4,976 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.